Development of methods characterization and identification of efavirenz in the mixtures and compositions with excipients by the method of FTIR-spectroscopy
- Authors: Beloborodov V.L1, Demina N.B1, Bakhrushina E.O1, Zolotov S.A2, Zolotova A.S3, Krasnyuk I.I1
-
Affiliations:
- Sechenov First Moscow State Medical University
- LLC «AMEDART»
- LLC «Farm-Sintez Lab»
- Issue: Vol 23, No 1 (2020)
- Pages: 9-15
- Section: Articles
- URL: https://journals.eco-vector.com/1560-9596/article/view/112710
- DOI: https://doi.org/10.29296/25877313-2020-01-02
- ID: 112710
Cite item
Abstract
Full Text
About the authors
V. L Beloborodov
Sechenov First Moscow State Medical University
Email: vlbe@list.ru
N. B Demina
Sechenov First Moscow State Medical University
Email: nbd217@mail.ru
E. O Bakhrushina
Sechenov First Moscow State Medical University
Email: nbd217@mail.ru
S. A Zolotov
LLC «AMEDART»
Email: duim50@gmail.com
A. S Zolotova
LLC «Farm-Sintez Lab»
Email: max_in_a@mail.ru
I. I Krasnyuk
Sechenov First Moscow State Medical University
Email: krasnyuki@mail.ru
References
- Vrouenraets S.M., Wit F.W., van Tongeren J., Lange J.M. Efavirenz: a review. Expert Opin. Pharmacother. 2007; 8(6):851- 871.
- Maggiolo F., Antimicrob J. Efavirenz: a decade of clinical experience in the treatment of HIV. Chemother. 2009; 64(5):910-928.
- Marzolini C., Telenti A., Decosterd L.A. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15(1):71-75.
- Chiappetta D.A., Hocht C., Sosnik A. Development and characterization of taste masked Efavirenz pellets utilizing hot melt extrusion. A Curr. HIV Res. 2002; 8(3):223-231.
- Zaheer A., Naveen M., Santosh M.K., Imran K. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Intern. J. Pharmatech. 2011; 3(1):807-823.
- Mishra N., Mishra M., Padh H. Formulation Development and Optimization of Efavirenz Loaded SLNs and NLCs using Plackett-Burman Design and its Statistical Elucidation Int. J. Pharma Res. Health Sci. 2018; 6(2):2379-2388.
- Cristofoletti R., Nair A., Abrahamsson B. et. al. Biowaiver monographs for immediate release solid oral dosage forms: efavirenz. J. Pharm. Sci. 2013; 102(2):318-329.
- Демина Н.Б. Биофармацевтическая классификационная система как инструмент разработки дизайна и технологии лекарственной формы. Разработка и регистрация лекарственных средств. 2017; 2:56-62
- Fitriani L., Haqi A., Zaini E. Preparation and characterization of solid dispersion freeze-dried efavirenz - polyvinylpyrrolidone K 30. Adv. Pharm. Technol. Res. 2016; 7:105-109
- da Costa M.A., Seiceira R.C., Rodrigues C.R., et al. Efavirenz dissolution enhancement : co-micronization. Pharmaceutics. 2013; 5:1-22
- Sathigari S., Chadha G., Lee Y. et al. Physicochemical Characterization of Efavirenz-Cyclodextrin Inclusion Complexes. AAPS Pharm. Sci. Tech. 2009; 10(1):81-87
- Chiappetta D.A., Hocht C., Taira C., Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Nanomedicine. 2010; 5:11-23.
- Chiappetta D.A., Hocht C., Taira C., Sosnik A. Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials. 2011; 32:2379-2387.
- Bharate S.S., Bharate S.B., Bajaj AN. Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review. J. Excipients Food Chem. 2010; 1(3):3-26.
- Chadha R., Bhandari S. Bhandari. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques. J. Pharm. Biomed. Anal. 2014; 87:82-87.
- Преч Э., Бюльманн Ф., Аффольтер К Определение строения органических соединений. Таблицы спектральных данных М.: Мир; БИНОМ, 2012. С. 258-302
- Mishraa S., Tandonb P., Ayalac A.P. Study on the structure and vibrational spectra of efavirenz conformers using DFT: Comparison to experimental data. Spectrochim. Acta Part A 88. 2012; 116-123.
- Marques M.M., Rezende C.A., Lima G.C. et al. New solid forms of efavirenz: Synthesis, vibrational spectroscopy and quantum chemical calculations. J. Molec. Struct. 2017; 1137:476-484.
- Perold Z., Swanepoel E., Brits M. Interaction and compatibility studies of efavirenz with pharmaceutical excipients. Am. J. Pharm. Tech. Res. 2012; 2(2):272-292.
- Wardhana Y.W., Soewandhi S.N., Suendo V. Polymorphic properties and dissolution profile of efavirenz due to solvents recrystallization. Int. J. Sci. Res. 2018; 7(7):724-727.
- Chadha R., Saini A., Arora P. An insight into thermodynamic relationship between polymorphic forms of efavirenz. J. Pharm. Pharmaceut. Sci. 2011; 15(2):234-251.
- Ravikumar K., Sridhar B. Molecular and crystal structure of efavirenz, a potent and specific inhibitor of HIV-1 reverse transcriptase, and its monohydrate. Mol. Cryst. Liq. Cryst. 2009; 515:190-198.
- de Melo A.C.C., de Amorim I.F., Cirqueira M.D.L., Martins F.T. Toward Novel Solid-State Forms of the Anti-HIV Drug Efavirenz: From Low Screening Success to Cocrystals Engineering Strategies and Discovery of a New Polymorph. Cryst. Growth Des. 2013; 13:1558-1569.
- Demina N.B. Current Trends in the Development of Technologies for Matrix Formulations with Modified Release (Review). Pharm. Chem. J. 2016; 50(7):475-480.